Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

Achyut Guleri, Riccardo Utili, Pascal Dohmen, Nicola Petrosillo, Cornelia Piper, Rashidkhan Pathan, Kamal Hamed

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The European Cubicin® Outcomes Registry and Experience (EU-CORESM) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE). Methods: Data from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Adverse events (AEs) were recorded during treatment and for up to 30 days post-treatment; follow-up data were collected for 2 years. Results: Of 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with both right- and left-sided IE (BRLIE). Overall clinical success was achieved in 80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%). Success rates for methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7% and 66.6% in patients with RIE, LIE and BRLIE, respectively. The overall sustained clinical success rate in patients followed for up to 2 years was 86.7% (RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs deemed possibly related to daptomycin in the investigator’s opinion were reported in 2 (1.3%) RIE, 18 (4.3%) LIE and 1 (2.1%) BRLIE patients. There were 11 (1.8%) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly related to daptomycin. Conclusion: Data from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.

Original languageEnglish
Pages (from-to)283-296
Number of pages14
JournalInfectious Diseases and Therapy
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 26 2015

Keywords

  • Daptomycin
  • Endocarditis
  • EU-CORE
  • Left-sided endocarditis
  • Right-sided endocarditis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin<sup>®</sup> Outcomes Registry and Experience (EU-CORE)'. Together they form a unique fingerprint.

Cite this